Marc N Hirt

List of Publications by Year in Descending Order

25 papers	1,269 citations	14 h-index	27 g-index
27 ext. papers	1,521 ext. citations	6.7 avg, IF	4.19 L-index

#	Paper	IF	Citations
25	Piezo2 is not an indispensable mechanosensor in murine cardiomyocytes.. *Scientific Reports*, **2022**, 12, 8193	4.9	0
24	Recapitulation of dyssynchrony-associated contractile impairment in asymmetrically paced engineered heart tissue. *Journal of Molecular and Cellular Cardiology*, **2021**, 163, 97-105	5.8	0
23	Hypertrophic signaling compensates for contractile and metabolic consequences of DNA methyltransferase 3A loss in human cardiomyocytes. *Journal of Molecular and Cellular Cardiology*, **2021**, 154, 115-123	5.8	0
22	Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy. *European Heart Journal*, **2020**, 41, 3462-3474	9.5	35
21	Assessment of Cardiotoxicity With Stem Cell-based Strategies. *Clinical Therapeutics*, **2020**, 42, 1892-1910	3.5	1
20	An Important Role for DNMT3A-Mediated DNA Methylation in Cardiomyocyte Metabolism and Contractility. *Circulation*, **2020**, 142, 1562-1578	16.7	9
19	Effects of the Delta Opioid Receptor Agonist DADLE in a Novel Hypoxia-Reoxygenation Model on Human and Rat-Engineered Heart Tissue: A Pilot Study. *Biomolecules*, **2020**, 10,	5.9	3
18	Blockade of miR-140-3p prevents functional deterioration in afterload-enhanced engineered heart tissue. *Scientific Reports*, **2019**, 9, 11494	4.9	4
17	Long Noncoding RNA-Enriched Vesicles Secreted by Hypoxic Cardiomyocytes Drive Cardiac Fibrosis. *Molecular Therapy - Nucleic Acids*, **2019**, 18, 363-374	10.7	44
16	A magnetics-based approach for fine-tuning afterload in engineered heart tissues. *ACS Biomaterials Science and Engineering*, **2019**, 5, 3663-3675	5.5	11
15	Toward Second-Generation Cardiomyogenic and Anti-cardiofibrotic 1,4-Dihydropyridine-Class TGF Inhibitors. *ChemMedChem*, **2019**, 14, 810-822	3.7	5
14	Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue. *Scientific Reports*, **2019**, 9, 18152	4.9	10
13	S100A4 as a Target of the E3-Ligase Asb2 and Its Effect on Engineered Heart Tissue. *Frontiers in Physiology*, **2018**, 9, 1292	4.6	2
12	Pharmacological inhibition of DNA methylation attenuates pressure overload-induced cardiac hypertrophy in rats. *Journal of Molecular and Cellular Cardiology*, **2018**, 120, 53-63	5.8	26
11	Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density. *Scientific Reports*, **2017**, 7, 5464	4.9	99
10	Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation. *Circulation*, **2016**, 134, 817-32	16.7	34
9	Human Engineered Heart Tissue: Analysis of Contractile Force. *Stem Cell Reports*, **2016**, 7, 29-42	8	217

8	Spontaneous Formation of Extensive Vessel-Like Structures in Murine Engineered Heart Tissue. *Tissue Engineering - Part A*, **2016**, 22, 326-35	3.9	16
7	General practitionerscadherence to chronic heart failure guidelines regarding medication: the GP-HF study. *Clinical Research in Cardiology*, **2016**, 105, 441-50	6.1	23
6	DNA methylation in an engineered heart tissue model of cardiac hypertrophy: common signatures and effects of DNA methylation inhibitors. *Basic Research in Cardiology*, **2016**, 111, 9	11.8	19
5	Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. *PLoS ONE*, **2016**, 11, e0145937	3.7	25
4	Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. *Journal of Molecular and Cellular Cardiology*, **2015**, 81, 1-9	5.8	38
3	Cardiac tissue engineering: state of the art. *Circulation Research*, **2014**, 114, 354-67	15.7	303
2	Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation. *Journal of Molecular and Cellular Cardiology*, **2014**, 74, 151-61	5.8	234
1	Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. *Basic Research in Cardiology*, **2012**, 107, 307	11.8	111